Atenção: Todas as denúncias são sigilosas e sua identidade será preservada.
Os campos nome e e-mail são de preenchimento opcional
Metadados | Descrição | Idioma |
---|---|---|
Autor(es): dc.contributor | Univ Med Ctr Utrecht | - |
Autor(es): dc.contributor | Univ Fed Parana | - |
Autor(es): dc.contributor | Universidade de São Paulo (USP) | - |
Autor(es): dc.contributor | Universidade Federal de São Paulo (UNIFESP) | - |
Autor(es): dc.contributor | Hosp Estadual Infantil Nossa da Senhora | - |
Autor(es): dc.contributor | Universidade Federal do Rio de Janeiro (UFRJ) | - |
Autor(es): dc.contributor | Universidade do Estado do Rio de Janeiro (UERJ) | - |
Autor(es): dc.contributor | Hosp Infantil Albert Sabin | - |
Autor(es): dc.contributor | Univ Florida | - |
Autor(es): dc.contributor | Hosp Crianca Brasilia Jose Alencar | - |
Autor(es): dc.contributor | Universidade Estadual de Campinas (UNICAMP) | - |
Autor(es): dc.contributor | Universidade Estadual Paulista (Unesp) | - |
Autor(es): dc.contributor | Natl Inst Publ Hlth & Environm RIVM | - |
Autor(es): dc.contributor | Hosp Canc Barretos | - |
Autor(es): dc.creator | Grein, Ingrid Herta Rotstein | - |
Autor(es): dc.creator | Pinto, Natalia Balera Ferreira | - |
Autor(es): dc.creator | Groot, Noortje | - |
Autor(es): dc.creator | Martins, Camila Bertini | - |
Autor(es): dc.creator | Lobo, Aline | - |
Autor(es): dc.creator | Aikawa, Nadia Emi | - |
Autor(es): dc.creator | Barbosa, Cassia | - |
Autor(es): dc.creator | Terreri, Maria Teresa | - |
Autor(es): dc.creator | Fraga, Aline Coelho Moreira da | - |
Autor(es): dc.creator | Oliveira, Sheila Knupp Feitosa de | - |
Autor(es): dc.creator | Sztajnbok, Flavio | - |
Autor(es): dc.creator | Paim Marques, Luciana B. | - |
Autor(es): dc.creator | Islabao, Aline Garcia | - |
Autor(es): dc.creator | Appenzeller, Simone | - |
Autor(es): dc.creator | Bica, Blanca | - |
Autor(es): dc.creator | Oliveira Sato, Juliana de [UNESP] | - |
Autor(es): dc.creator | Magalhaes, Claudia Saad [UNESP] | - |
Autor(es): dc.creator | Ferriani, Virginia | - |
Autor(es): dc.creator | Pasmans, Hella | - |
Autor(es): dc.creator | Schepp, Rutger | - |
Autor(es): dc.creator | van der Klis, Fiona | - |
Autor(es): dc.creator | Roock, Sytze de | - |
Autor(es): dc.creator | Wulffraat, Nico | - |
Autor(es): dc.creator | Pileggi, Gecilmara Salviato | - |
Data de aceite: dc.date.accessioned | 2022-02-22T00:57:12Z | - |
Data de disponibilização: dc.date.available | 2022-02-22T00:57:12Z | - |
Data de envio: dc.date.issued | 2021-06-25 | - |
Data de envio: dc.date.issued | 2021-06-25 | - |
Data de envio: dc.date.issued | 2020-11-10 | - |
Fonte completa do material: dc.identifier | http://dx.doi.org/10.1186/s12969-020-00479-w | - |
Fonte completa do material: dc.identifier | http://hdl.handle.net/11449/209646 | - |
Fonte: dc.identifier.uri | http://educapes.capes.gov.br/handle/11449/209646 | - |
Descrição: dc.description | Background: Concerns about the safety and efficacy of vaccines in patients with autoimmune diseases (AID) have led to contradictions and low vaccination coverage in this population, who are at a higher risk of infections, including by human papillomavirus (HPV). Although HPV vaccines have been recommended for immunocompromised patients, there is still a lack of data to support its use for AID patients, such as juvenile dermatomyositis (JDM) patients. The aim of this study was to assess the safety and immunogenicity of the quadrivalent HPV (qHPV) vaccine in a cohort of JDM patients. Methods: JDM patients aged from 9 to 20 years and healthy controls (HC) were enrolled to receive a 3-dose schedule of qHPV vaccine from March/2014 to March/2016. Study visits were performed before the first dose, 1 month after the second and third doses, and 6 months after the third dose. Participants completed a diary of possible adverse events for 14 days following each dose of vaccination (AEFV). Disease activity and current therapy were analyzed at each visit for JDM patients. In addition, serum samples from all participants were collected to test antibody concentrations against HPV16 and 18 at each visit. Participant recruitment was conducted in ten Brazilian centres. From 47 eligible JDM patients and 41 HC, 42 and 35, respectively, completed the 3-dose schedule of the vaccine, given that five JDM patients and two HC had received doses prior to their inclusion in the study. Results: The AEFVs presented by the participants were mild and in general did not differ between JDM and HC groups. No severe AEFVs were related to the vaccination. Disease activity was stable, or even improved during the follow-up. One month after the third dose of the vaccine the JDM group presented seropositivity of 100% for HPV16 and 97% for HPV18, similarly to the HC group, who presented 100% for both serotypes (p = 1.000). Six months after the third dose the seropositivity for the patient group was 94% for both HPV types. Conclusions: The HPV vaccination in this cohort of JDM patients was safe and immunogenic. Since the seropositivity against HPV16 and 18 was very high after the 3-dose schedule, this regimen should be recommended for JDM patients. | - |
Descrição: dc.description | Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Paediat Immunol & Rheumatol, Utrecht, Netherlands | - |
Descrição: dc.description | Univ Fed Parana, Hosp Clin, Dept Pediat, Gen Carneiro St 68,181, BR-80060900 Curitiba, Parana, Brazil | - |
Descrição: dc.description | Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Paediat, Sao Paulo, Brazil | - |
Descrição: dc.description | Univ Fed Sao Paulo, Dept Prevent Med, Sao Paulo, Brazil | - |
Descrição: dc.description | Univ Sao Paulo, Fac Med, Hosp Clin, Dept Paediat Rheumatol,Inst Crianca, Sao Paulo, Brazil | - |
Descrição: dc.description | Univ Fed Sao Paulo, Dept Paediat Rheumatol, Sao Paulo, Brazil | - |
Descrição: dc.description | Hosp Estadual Infantil Nossa da Senhora, Dept Paediat Rheumatol, Vitoria, ES, Brazil | - |
Descrição: dc.description | Univ Fed Rio de Janeiro, Inst Puericultura & Pediat Martagao Gesteira IPPM, Dept Paediat Rheumatol, Rio De Janeiro, Brazil | - |
Descrição: dc.description | Univ Estado Rio De Janeiro, Dept Paediat Rheumatol, Rio De Janeiro, Brazil | - |
Descrição: dc.description | Hosp Infantil Albert Sabin, Dept Paediat Rheumatol, Fortaleza, Ceara, Brazil | - |
Descrição: dc.description | Univ Florida, Dept Paediat Immunol & Rheumatol, Coll Med, Gainesville, FL 32611 USA | - |
Descrição: dc.description | Hosp Crianca Brasilia Jose Alencar, Dept Paediat Rheumatol, Brasilia, DF, Brazil | - |
Descrição: dc.description | Univ Estadual Campinas, Dept Paediat Rheumatol, Sao Paulo, Brazil | - |
Descrição: dc.description | Univ Fed Rio de Janeiro, Dept Paediat Rheumatol, Rio De Janeiro, Brazil | - |
Descrição: dc.description | Univ Estadual Paulista, Dept Paediat Rheumatol, Botucatu, SP, Brazil | - |
Descrição: dc.description | Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Paediat Rheumatol, Sao Paulo, Brazil | - |
Descrição: dc.description | Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, Bilthoven, Netherlands | - |
Descrição: dc.description | Hosp Canc Barretos, Fac Ciencias Saude Dr Paulo Prata FACISB, Sao Paulo, Brazil | - |
Descrição: dc.description | Hosp Canc Barretos, Inst Ensino & Pesquisa IEP, Sao Paulo, Brazil | - |
Descrição: dc.description | Univ Estadual Paulista, Dept Paediat Rheumatol, Botucatu, SP, Brazil | - |
Formato: dc.format | 12 | - |
Idioma: dc.language | en | - |
Publicador: dc.publisher | Bmc | - |
Relação: dc.relation | Pediatric Rheumatology | - |
???dc.source???: dc.source | Web of Science | - |
Palavras-chave: dc.subject | Juvenile dermatomyositis | - |
Palavras-chave: dc.subject | Quadrivalent HPV vaccine | - |
Palavras-chave: dc.subject | Safety | - |
Palavras-chave: dc.subject | Immunogenicity | - |
Título: dc.title | Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study | - |
Tipo de arquivo: dc.type | livro digital | - |
Aparece nas coleções: | Repositório Institucional - Unesp |
O Portal eduCAPES é oferecido ao usuário, condicionado à aceitação dos termos, condições e avisos contidos aqui e sem modificações. A CAPES poderá modificar o conteúdo ou formato deste site ou acabar com a sua operação ou suas ferramentas a seu critério único e sem aviso prévio. Ao acessar este portal, você, usuário pessoa física ou jurídica, se declara compreender e aceitar as condições aqui estabelecidas, da seguinte forma: